ABL Bio Inc. / Sanofi S.A. (ABL301 license to Sanofi)

Parkinson's Disease (Disease-Modifying)

1M US cases/yr · $6.8B Global Parkinson's pharmacotherapy market 2023 · 0 FDA-approved disease-modifying therapies (symptomatic only)

Disease Overview

Parkinson's disease is the second most common neurodegenerative disorder after Alzheimer's, affecting approximately 1 million Americans with roughly 90,000 new diagnoses each year and prevalence projected to nearly double by 2040 as the population ages. Pathologically, Parkinson's is defined by progressive loss of dopaminergic neurons in the substantia nigra and accumulation of misfolded alpha-synuclein in Lewy bodies, producing motor symptoms (bradykinesia, rigidity, resting tremor, postural instability) and a wide spectrum of non-motor features (cognitive decline, autonomic dysfunction, sleep disorders, depression). Standard-of-care remains symptomatic — levodopa/carbidopa, dopamine agonists, MAO-B and COMT inhibitors, and device-based therapies (deep brain stimulation, levodopa-carbidopa intestinal gel) — with no approved disease-modifying therapy despite billions in R&D investment over three decades. The unmet need at the disease-modifying frontier is enormous, with anti-alpha-synuclein antibody programs from Roche/Prothena (prasinezumab) and Biogen (cinpanemab, discontinued) historically failing to meet primary endpoints; ABL301's bispecific design with brain penetration via an IGF1R BBB shuttle (Grabody-B) is positioned to overcome the CNS exposure limitations that hobbled prior programs.

Competitive Landscape

The disease-modifying Parkinson's competitive landscape represents the largest unmet need in CNS pharma and a graveyard of high-profile late-stage failures. Anti-alpha-synuclein passive immunotherapy is the dominant modality: prasinezumab (Roche/Prothena) is in Phase 2b PADOVA following the failed PASADENA primary endpoint that nonetheless yielded encouraging secondary motor signals; cinpanemab (Biogen/Neurimmune) was discontinued in 2021 after Phase 2 SPARK missed. Active vaccines (UB-312 from Vaxxinity, ACI-7104 from AC Immune) are in earlier-stage trials targeting endogenous antibody generation. LRRK2 inhibitors are advanced by Denali/Biogen (BIIB122/DNL151) in LUMA and LIGHTHOUSE Phase 2/3 studies, particularly in LRRK2-mutation-positive populations. GBA1 small-molecule modulators include Vertex/Prevail's PR001 AAV gene therapy and Lysosomal Therapeutics' programs. Sanofi/ABL Bio's bispecific approach is differentiated by IGF1R-mediated CNS penetration aiming for 5-30x higher brain exposure than conventional monoclonal antibodies, directly addressing the central pharmacology gap that hobbled prior failures — namely insufficient CNS exposure to engage extracellular and synaptic alpha-synuclein. Symptomatic anchors remain levodopa-based regimens (Sinemet generic, Rytary, Inbrija inhaled), MAO-B inhibitors (Azilect, Xadago), COMT inhibitors (Comtan, Ongentys), dopamine agonists, and adenosine A2A antagonists (Nourianz, Kyowa Kirin), with device-based therapies (DBS, Duopa/levodopa-carbidopa intestinal gel) reserved for advanced disease.